Immutep
Germany - BerlinBiotechnology
Focus: Immutep is a Berlin-based biotechnology company focused on cell therapies and antibodies, operating at pre-commercial stage with a pipeline concentrated in oncology immunotherapy.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Immutep
AI assessmentNot HiringNo open roles listed right now. Follow Immutep to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
IMP321
Solid TumorsClinical Trials (1)
NCT03252938Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
Phase 1Help build intelligence for Immutep
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.